Mutant KRAS at the heart of tumor immune evasion

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i> -Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335 · see citing works

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R. A., Vecchio, M. D., Atkinson, V. G., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Giacomo, A. M. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 326 · see citing works

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203 · see citing works

Kras and tumor immunity: friend or foe?

Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85 · see citing works

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

Bardia, A., Gounder, M., Rodón, J., Janku, F., Lolkema, M., Stephenson, J., Bédard, P., Schuler, M., Sessa, C., LoRusso, P., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0297 · Cited by 79 · see citing works

Progress in targeting RAS with small molecule drugs

McCormick, F. P. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 63 · see citing works

Abstract LB-C09: the KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

Briere, D. M., Calinisan, A., Aranda, R., Sudhakar, N., Hargis, L., Gatto, S., Fernandez-Banet, J., Pavlicek, A., Engstrom, L. D., Hallin, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-19-lb-c09 · Cited by 13 · see citing works

KRAS Mutation: From Undruggable to Druggable in Cancer

Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127 · see citing works

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136 · see citing works

Unlocking G-Quadruplexes as Antiviral Targets

Abiri, A., Lavigne, M., Rezaei, M., Nikzad, S., Zare, P., Mergny, J., & Rahimi, H. R. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000230 · Cited by 123 · see citing works

Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death

Zhou, C., Li, W., Zhenxing, L., Wu, X., Cheng, S., Peng, J., Zeng, K., Li, W., Lan, P., Yang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44779-1 · Cited by 100 · see citing works

Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues

Şahin, İ. H., Ciombor, K. K., Diaz, L. A., Yu, J. B., & Kim, R. D. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349811 · Cited by 72 · see citing works

Overcoming Resistance to Drugs Targeting KRAS Mutation

Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61 · see citing works

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer

Ros, J., Balconi, F., Baraibar, I., Gonzalez, N. S., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1112276 · Cited by 63 · see citing works

Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations

Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 56 · see citing works

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy

Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 45 · see citing works

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers

Feng, J., Xiao, X., Xia, X., Min, J., Tang, W., Shi, X., Xu, K., Zhou, G., Li, K., Shen, P., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.006 · Cited by 38 · see citing works

Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease

Hartmann, O., Reissland, M., Maier, C. R., Fischer, T., Prieto‐Garcia, C., Baluapuri, A., Schwarz, J. D., Schmitz, W., Garrido‐Rodríguez, M., Pahor, N., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641618 · Cited by 38 · see citing works

Targeting RAS oncogenesis with SOS1 inhibitors

Hillig, R. C., & Bader, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.001 · Cited by 32 · see citing works

Biology, pathology, and therapeutic targeting of RAS

Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 28 · see citing works

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 25 · see citing works

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications

Kilowski, K. A., Dietrich, M. F., Xiu, J., Baca, Y., Hinton, A. C., Ahmad, S., Herzog, T. J., Thaker, P. H., & Holloway, R. W. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.10.026 · Cited by 23 · see citing works

Inhibition of RAS: proven and potential vulnerabilities

Zuberi, M., Khan, I., & O’Bryan, J. P. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190023 · Cited by 20 · see citing works

A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation

Wang, S. H., Cao, Z., Farazuddin, M., Chen, J., Janczak, K. W., Tang, S., Cannon, J., & Baker, J. R. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-023-00717-9 · Cited by 18 · see citing works

Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications

wang, F., Gao, X., Wang, P., He, H., Chen, P., Liu, Z., Chen, Y., Zhou, H., Chen, W., Yi, X., et al. (2021) · Frontiers in Immunology · doi:10.2139/ssrn.3970711 · Cited by 17 · see citing works

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 14 · see citing works

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy

Ramos-Ramírez, M., Caballé‐Perez, E., Lucio-Lozada, J., Romero-Núñez, E., Castillo-Ruiz, C., Dorantes-Sánchez, L., Flores‐Estrada, D., Recondo, G., Barrios‐Bernal, P., Cabrera-Miranda, L. A., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10245-7 · Cited by 11 · see citing works

AZD4625 is a Potent and Selective Inhibitor of KRASG12C

Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9 · see citing works

Leveraging a KRAS-based signature to predict the prognosis and drug sensitivity of colon cancer and identifying SPINK4 as a new biomarker

Huo, J.-T., Tuersun, A., Yu, S.-Y., Zhang, Y., Feng, W., Xu, Z., Zhao, J., Zong, Y., & Lu, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-48768-0 · Cited by 6 · see citing works

Discoveries in the redox regulation of KRAS

Kramer‐Drauberg, M., & Ambrogio, C. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105901 · Cited by 6 · see citing works

Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer

Nounsi, A., Seitlinger, J., Ponté, C., Demiselle, J., Idoux‐Gillet, Y., Pencreach, E., Beau‐Faller, M., Lindner, V., Balloul, J., Quéméneur, É., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071824 · Cited by 6 · see citing works

KRas plays a negative role in regulating IDO1 expression

Peng, X., Lee, E., liang, J., Colon, T. M., Tran, F., Choi, B. H., & Dai, W. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102167 · Cited by 5 · see citing works

Advances on drug therapy for KRAS-mutant non-small-cell lung cancer

Tian, T., & Li, W. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102668 · Cited by 4 · see citing works

Systematic and precise interventions for KRAS-mutant cancers

Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 3 · see citing works

Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin

Ohana, J., Sandler, U., Devary, O. V., & Devary, Y. (2023) · Oncotarget · doi:10.18632/oncotarget.28467 · Cited by 2 · see citing works

Immunotherapy in pMMR/MSS Metastatic Colorectal Cancer

Colombo, A., Cordio, S. S., Gebbia, V., Piazza, D., & Porretto, C. M. (2024) · Nature Cell and Science · doi:10.61474/ncs.2023.00031 · Cited by 1 · see citing works

Imaging mass cytometry in preclinical studies of lung cancer

van Maldegem, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822213-3.00004-8 · Cited by 1 · see citing works

Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Report and Literature Review

Taboada, R. G., Almeida, M. F. A., Santiago, K. M., Carraro, D. M., Nunes, W. A., Diniz, A. L., Felismino, T. C., & de Jesus, V. H. F. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01140-5 · Cited by 1 · see citing works

The bone marrow microenvironment of RAS pathway mutant B-ALL is enriched for immunosuppressive regulatory T cellsPreprint

Blanco, M. N. F., Kazybay, B., Perzolli, A., Kester, L. A., Heidenreich, O. T., & Vormoor, H. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.17.712388

Targeting Mutant KRAS for Immunogenic Cell Death Induction

Galluzzi, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.004 · Cited by 4 · see citing works

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy

Boumelha, J., Molina‐Arcas, M., & Downward, J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3655 · Cited by 44 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

MA12.03 Mechanims of Immune Evasion in Patients With KRAS-Mutant Lung Adenocarcinoma: A Role of MAPK Pathway Activation

Naves, D. D., van Ee, T. J., van Maldegem, F., de Gruijl, T. D., van Kooyk, Y., & Radonic, T. R. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.07.143 · Cited by 1 · see citing works

Targeting KRAS : Crossroads of Signaling and Immune Inhibition

Kato, S., Fujiwara, Y., & Hong, D. S. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-5 · Cited by 14 · see citing works